Skip to main content
OpenTrials

Clinical trial condition

Hemoglobinuria, Paroxysmal

Explore clinical trials studying Hemoglobinuria, Paroxysmal. Study availability and eligibility vary by location and protocol.

159 public trials 28 recruiting studies
Refine in advanced search Browse all conditions

Hemoglobinuria, Paroxysmal trial results

Completed

Danicopan as Add-on Therapy to a C5 Inhibitor in Paroxysmal Nocturnal Hemoglobinuria (PNH) Participants Who Have Clinically Evident Extravascular Hemolysis (EVH)(ALPHA)

NCT04469465

Conditions
Anemia, Anemia, Hemolytic, Bone Marrow Diseases, +8 more
Locations
  • Research Site Los Angeles, California, United States
  • Research Site Weston, Florida, United States
  • Research Site Chicago, Illinois, United States
  • Research Site Kalamazoo, Michigan, United States
View all 62 locations
View Trial Details
Completed

Treating Paroxysmal Nocturnal Haemoglobinuria Patients With rVA576

NCT03588026

Conditions
Anemia, Anemia, Hemolytic, Bone Marrow Diseases, +5 more
Locations
  • Almaty City Hospital No.7 Almaty, Microdistrict Kalkaman, Kazakhstan
  • Vilnius University Hospital Santaros Klinikos , Santariškių St. 2, LT-08661, Vilnius, Lithuania
  • University of Kelaniya, Faculty of Medicine, Thalagolla Road Colombo, Sri Lanka
View Trial Details
Completed

Pozelimab and Cemdisiran Combination Treatment in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Who Have Received Pozelimab Monotherapy

NCT04811716

Conditions
Anemia, Anemia, Hemolytic, Bone Marrow Diseases, +5 more
Locations
  • Prince of Wales Hospital Hong Kong, New Territories
  • D l Pesti Centrumk rh z Orsz gos Hematol giai s Infektol giai Int zet Budapest, Nagyvárad Tér 1, Hungary
  • Hospital Miri Miri, Sarawak, Malaysia
  • Hospital Sibu Sibu, Sarawak, Malaysia
View all 13 locations
View Trial Details
Completed

ALXN1210 Versus Eculizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab

NCT03056040

Conditions
Anemia, Anemia, Hemolytic, Bone Marrow Diseases, +5 more
Locations
  • Research Site Duarte, California, United States
  • Research Site Los Angeles, California, United States
  • Research Site Baltimore, Maryland, United States
  • Research Site Detroit, Michigan, United States
View all 51 locations
View Trial Details
Completed

Study of Efficacy and Safety of Twice Daily Oral Iptacopan (LNP023) in Adult PNH Patients Who Are Naive to Complement Inhibitor Therapy

NCT04820530

Conditions
Anemia, Anemia, Hemolytic, Bone Marrow Diseases, +5 more
Locations
  • Novartis Investigative Site Beijing, China
  • Novartis Investigative Site Tianjin, China
  • Novartis Investigative Site Tianjin, China
  • Novartis Investigative Site Paris, France
View Trial Details
Completed

Study of Efficacy and Safety of Twice Daily Oral LNP023 in Adult PNH Patients With Residual Anemia Despite Anti-C5 Antibody Treatment

NCT04558918

Conditions
Anemia, Anemia, Hemolytic, Bone Marrow Diseases, +5 more
Locations
  • City Of Hope National Med Center City of Hope Medical Center Duarte, California, United States
  • Univ Cali Irvine ALS Neuromuscular Orange, California, United States
  • Augusta University Georgia Patient Treatment Augusta, Georgia, United States
  • Levine Cancer Insitute Carolinas Healthcare System Charlotte, North Carolina, United States
View all 39 locations
View Trial Details

Related conditions